Page last updated: 2024-12-11

rhodoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rhodoquinone: methoxy group of ubiquinone substituted with amino group; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6441300
SCHEMBL ID932613
MeSH IDM0044325

Synonyms (14)

Synonym
rhodoquinone
rhodoquinone-10
2-amino-5-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-3-methoxy-6-methylcyclohexa-2,5-diene-1,4-dione
2-amino-5-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontanedecaenyl)-3-methoxy-6-methyl-p-benzoquinone
5591-74-2
einecs 227-003-1
unii-jvc3puu81f
jvc3puu81f ,
rhodoquinone [mi]
p-benzoquinone, 2-amino-5-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-3-methoxy-6-methyl-
2,5-cyclohexadiene-1,4-dione, 2-amino-5-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-3-methoxy-6-methyl-
2,5-cyclohexadiene-1,4-dione, 2-amino-5-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-3-methoxy-6-methyl-
SCHEMBL932613
Q27281715

Research Excerpts

Overview

Rhodoquinone (RQ) is a required cofactor for anaerobic respiration in Rhodospirillum rubrum. It is also found in several helminth parasites that utilize a fumarate reductase pathway.

ExcerptReferenceRelevance
"Rhodoquinone (RQ) is an important cofactor used in the anaerobic energy metabolism of Rhodospirillum rubrum. "( Evidence that ubiquinone is a required intermediate for rhodoquinone biosynthesis in Rhodospirillum rubrum.
Brajcich, BC; Clarke, CF; Hotchko, MJ; Iarocci, AL; Johnstone, LA; Kieffer, A; Lonjers, ZT; Mandel, SM; Marbois, BN; Morgan, RK; Muhs, JD; Reynolds, BJ; Shepherd, JN, 2010
)
2.05
"Rhodoquinone (RQ) is a required cofactor for anaerobic respiration in Rhodospirillum rubrum, and it is also found in several helminth parasites that utilize a fumarate reductase pathway. "( Identification of a new gene required for the biosynthesis of rhodoquinone in Rhodospirillum rubrum.
Anders, KR; Chu, TP; Dickson, EL; Kreutz, JE; Lonjers, ZT; Neacsu, FA; Shepherd, JN, 2012
)
2.06
"Rhodoquinone (RQ) is an essential component of the electron transport associated with this fumarate reduction, whereas ubiquinone (UQ) is used in the aerobic energy metabolism of parasites."( Rhodoquinone is synthesized de novo by Fasciola hepatica.
Flesch, FM; Gaasenbeek, CP; Luijten, M; Tielens, AG; Van Hellemond, JJ, 1996
)
2.46

Actions

ExcerptReferenceRelevance
"Rhodoquinone, with its lower redox potential than ubiquinone, is capable of donating electrons to fumarate."( The electron transport chain in anaerobically functioning eukaryotes.
Tielens, AG; Van Hellemond, JJ, 1998
)
1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
rhodoquinone-10 biosynthesis05

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (21.95)18.7374
1990's10 (24.39)18.2507
2000's9 (21.95)29.6817
2010's10 (24.39)24.3611
2020's3 (7.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.18 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (9.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (90.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]